Fredun Pharmaceuticals Limited

BSE: FREDUN539730ISIN INE194R01017

Healthcare
Pharmaceuticals
BSE Healthcare

Share price

₹1,509.60+54.70 (+3.76%)

as of 4 Nov 2026

Prices adjusted for splits and bonuses; cash dividends excluded. Volume shows actual shares traded.

Splits and bonuses

16 Jul 2026 · Bonus 2:1

52W high: ₹1,666.35
52W low: ₹454.05
Off 52W high: -9.41%
1M return: +10.46%
3M return: +14.95%
6M return: +83.76%
1Y return: +192.87%
20D avg volume: 18,436
50 DMA: ₹1,423.37
200 DMA: ₹929.04

Key ratios Consolidated

Market cap: ₹2,497 Cr
Current price: ₹1,509.60
52W high / low: ₹1,666.35 / ₹454.05
Face value: ₹10.00
P/E: 58.22
P/B: —
EPS (TTM): ₹25.93
Book value / share: —
ROE: —
ROCE: 25.00%
Operating margin: —
Net margin: —
Debt / equity: 0.80
Net debt: ₹157.47 Cr
Interest cover: 2.20
Dividend yield: 0.05%
Dividend / share (TTM): ₹0.70
Payout: 2.70%
Cash conversion cycle: 158.4 days

Financials

Metric	Q1 FY27	Q4 FY26	Q3 FY26	Q2 FY26	Q1 FY26	Q4 FY25	Q4 FY24
Income statement
	227.76	210.41	159.93	143.59	119.40	165.44	—
	0.49	2.64	1.00	1.71	0.45	1.97	—
	228.25	213.06	160.92	145.29	119.86	167.41	—
	207.70	201.81	146.92	132.59	110.81	160.14	—
	179.73	173.54	118.91	100.44	91.08	125.01	—
	0.00	0.00	0.00	0.00	0.00	0.00	—
	7.12	8.86	8.15	8.30	7.63	9.70	—
	8.62	14.49	10.55	7.73	6.53	8.15	—
	3.57	3.15	1.78	1.89	1.42	1.84	—
	15.01	23.86	14.88	9.81	10.81	16.68	—
	20.55	11.25	14.00	12.71	9.04	7.26	—
	0.00	0.00	0.00	0.00	0.00	0.00	—
	20.55	11.25	14.00	12.71	9.04	7.26	—
	7.42	0.47	3.52	3.27	2.27	1.26	—
	13.13	10.78	10.48	9.43	6.77	6.00	—
	23.82	19.70	19.53	19.98	14.33	12.71	—
Key metrics
	32.74	28.89	26.33	22.33	16.99	17.25	—
	14.40%	13.70%	16.50%	15.60%	14.20%	10.40%	—
	5.80%	5.10%	6.60%	6.60%	5.70%	3.60%	—
	—	7.50%	—	10.40%	—	9.30%	—
	90.80%	27.20%	—	—	—	—	—
	93.90%	79.70%	—	—	—	—	—

Metric	TTM	FY26	FY25	FY24
Income statement
	741.69	633.33	451.71	—
	5.84	5.80	4.56	—
	747.52	639.12	456.27	—
	689.02	592.13	428.77	—
	572.62	480.76	323.98	—
	0.00	0.00	0.00	—
	32.43	32.94	22.23	—
	41.39	39.30	22.38	—
	10.39	8.25	5.04	—
	63.56	62.57	49.10	—
	58.51	47.00	27.49	—
	0.00	0.00	0.00	—
	58.51	47.00	27.49	—
	14.68	14.38	7.75	—
	43.82	32.62	19.74	—
	83.03	66.81	44.83	—
Key metrics
	110.29	94.55	54.91	—
	14.87%	14.90%	12.20%	—
	5.91%	5.20%	4.40%	—
	—	25.00%	30.00%	—
	—	40.20%	—	—
	—	65.20%	—	—
	—	-47.31	-35.17	—
	—	0.81	-1.47	—
	—	0.80	1.18	—
	—	157.47	166.50	—
	—	158.4	219.9	—
Balance sheet
	—	642.08	487.41	—
	—	498.17	427.95	—
	—	64.93	0.64	—
	—	92.69	177.12	—
	—	269.80	239.89	—
	—	15.28	3.30	—
	—	117.63	52.49	—
	—	87.58	144.77	—
	—	296.86	321.18	—
	—	222.40	167.14	—
	—	166.09	150.61	—
	—	56.31	16.53	—
	—	278.11	141.38	—
Cash flow
	—	26.28	-29.06	—
	—	-73.59	-6.35	—
	—	121.45	39.12	—
	—	73.59	6.11	—

Metric	Q1 FY27	Q4 FY26	Q3 FY26	Q2 FY26	Q1 FY26	Q4 FY25	Q3 FY25	Q2 FY25	Q1 FY25	Q4 FY24	Q3 FY24	Q2 FY24
Income statement
	227.76	210.41	159.93	143.59	119.40	165.44	101.84	106.89	77.54	117.21	86.66	81.48
	0.49	2.64	1.00	1.71	0.45	1.97	0.86	0.46	1.27	0.82	0.35	0.50
	228.25	213.05	160.92	145.29	119.86	167.41	102.70	107.35	78.81	118.03	87.01	81.98
	207.66	201.52	146.92	132.29	110.81	159.37	95.56	99.78	73.29	112.19	81.24	76.22
	179.73	173.54	118.91	99.26	91.08	125.01	72.66	67.40	57.51	91.57	75.56	81.67
	0.00	0.00	0.00	0.00	0.00	0.00	—	—	—	—	—	—
	7.12	8.86	8.15	8.30	7.63	9.70	5.85	3.58	3.10	3.90	2.97	2.93
	8.62	14.49	10.55	7.73	6.53	8.15	5.00	5.31	3.91	4.37	3.77	2.90
	3.57	3.11	1.78	1.60	1.42	1.25	1.09	1.06	1.05	0.96	0.99	0.94
	14.97	23.61	14.88	10.99	10.81	16.49	5.97	9.07	4.40	8.93	6.49	3.28
	20.59	11.53	14.00	13.01	9.04	8.04	7.13	7.58	5.52	5.84	5.76	5.77
	0.00	0.00	0.00	0.00	0.00	0.00	—	—	—	—	—	—
	20.59	11.53	14.00	13.01	9.04	8.04	7.13	7.58	5.52	5.84	5.76	5.77
	7.42	0.47	3.52	3.27	2.27	0.97	1.80	3.30	1.39	0.78	1.54	1.83
	13.17	11.07	10.48	9.73	6.77	7.07	5.33	4.27	4.13	5.06	4.22	3.94
	23.89	20.22	19.53	20.61	14.33	14.98	11.29	9.05	8.79	10.77	8.99	8.40
Key metrics
	32.78	29.13	26.33	22.34	16.99	17.44	13.22	13.95	10.48	11.17	10.52	9.61
	14.40%	13.80%	16.50%	15.60%	14.20%	10.50%	13.00%	13.10%	13.50%	9.50%	12.10%	11.80%
	5.80%	5.30%	6.60%	6.80%	5.70%	4.30%	5.20%	4.00%	5.30%	4.30%	4.90%	4.80%
	—	7.50%	—	10.60%	—	10.20%	—	—	—	—	—	—
	90.80%	27.20%	57.00%	34.30%	54.00%	41.10%	17.50%	31.20%	—	—	—	—
	94.50%	56.60%	96.60%	127.90%	63.90%	39.70%	26.30%	8.40%	—	—	—	—

Metric	TTM	FY26	FY25	FY24	FY23	FY22
Income statement
	741.69	633.33	451.71	346.58	274.34	221.74
	5.84	5.80	4.56	2.50	2.16	4.35
	747.51	639.12	456.27	349.07	276.50	226.09
	688.39	591.54	428.00	327.62	258.99	217.49
	571.44	480.76	323.98	282.42	245.57	176.45
	0.00	0.00	0.00	—	—	—
	32.43	32.94	22.23	12.50	11.53	10.66
	41.39	39.30	22.38	13.65	9.28	4.67
	10.06	7.91	4.45	3.80	2.81	2.16
	64.45	62.32	48.91	22.73	17.10	15.75
	59.13	47.58	28.27	21.45	17.51	8.60
	0.00	0.00	0.00	—	—	—
	59.13	47.58	28.27	21.45	17.51	8.60
	14.68	14.38	7.46	5.83	6.70	2.27
	44.45	33.21	20.81	15.62	10.81	6.33
	84.25	68.01	44.83	33.66	22.93	14.29
Key metrics
	110.58	94.79	55.10	38.90	29.60	15.43
	14.91%	15.00%	12.20%	11.20%	10.80%	7.00%
	5.99%	5.20%	4.60%	4.50%	3.90%	2.90%
	—	25.10%	31.80%	—	—	—
	50.27%	40.20%	30.30%	26.30%	23.70%	—
	89.63%	59.60%	33.20%	44.50%	70.80%	—
	—	-42.77	-34.87	—	—	—
	—	0.93	-1.39	—	—	—
	—	0.80	1.18	—	—	—
	—	157.13	166.17	—	—	—
	—	158.5	219.9	—	—	—
Balance sheet
	—	642.14	486.65	—	—	—
	—	498.24	427.53	—	—	—
	—	64.90	0.23	—	—	—
	—	92.69	177.12	—	—	—
	—	269.80	239.89	—	—	—
	—	15.25	3.29	—	—	—
	—	117.61	52.14	—	—	—
	—	87.47	144.76	—	—	—
	—	296.31	327.32	—	—	—
	—	222.03	166.40	—	—	—
	—	165.72	156.79	—	—	—
	—	56.31	9.61	—	—	—
	—	278.71	141.40	—	—	—
Cash flow
	—	30.81	-28.88	—	—	—
	—	-73.58	-5.99	—	—	—
	—	121.82	38.34	—	—	—
	—	73.58	5.99	—	—	—

Compounded growth

Standalone

Sales CAGR 3Y: +32.16%
Sales CAGR 5Y: —
Profit CAGR 3Y: +45.37%
Profit CAGR 5Y: —
Sales YoY (TTM): +50.27%
Profit YoY (TTM): +89.63%

Consolidated

Sales CAGR 3Y: —
Sales CAGR 5Y: —
Profit CAGR 3Y: —
Profit CAGR 5Y: —
Sales YoY (TTM): —
Profit YoY (TTM): —

Compounded from reported annual figures. We publish no share-price CAGR: our prices are as-traded, so one would be wrong across every split and bonus issue.

Shareholding as of 30 Sep 2026

Promoter holding: 43.62%

Quarter	September 2026	June 2026
Promoter %	43.62%	44.57%

Holder	Type	Holding	Previous	Change
DAULAT NARIMAN MEDHORA	Promoter	38.53%	39.37%	-0.84%
NIKHIL KISHORCHANDRA VORA	Public	5.28%	5.43%	-0.15%
FREDUN NARIMAN MEDHORA	Promoter	5.08%	5.19%	-0.11%
ALCHEMY LONG TERM VENTURES FUND, SERIES 2	Public	1.42%	—	—
AJAY KUMAR AGGARWAL	Public	1.42%	—	—
BANK OF INDIA	Public	1.33%	1.36%	-0.03%
ARUN KUMAR MUKHERJEE	Public	1.31%	1.24%	+0.07%
ALCHEMY CAPITAL MANAGEMENT PVT LTD	Public	1.07%	—	—
CAPRI GLOBAL VENTURES PRIVATE LIMITED	Public	1.01%	1.45%	-0.44%
NARIMAN BAMANSHA MEDHORA	Promoter	0.01%	0.01%	0.00%

Public shareholders are disclosed individually only above 1%.

Peer comparison

Company	Mkt cap (₹ Cr)	Price (₹)	P/E	ROCE	Sales YoY	Profit YoY	1Y return
Sun Pharmaceutical Industries Ltd.	4,26,112	1,776.00	38.78	17.90%	+12.13% TTM	+4.79% TTM	+4.92%
Divi's Laboratories Ltd.	2,66,424	10,036.00	91.09	19.00%	+16.35% TTM	+26.84% TTM	+47.61%
Torrent Pharmaceuticals Ltd.	1,79,908	4,730.00	85.71	9.10%	+42.06% TTM	-1.92% TTM	+32.24%
Laurus Labs Limited	1,24,601	2,306.10	93.53	19.70%	+23.03% TTM	+95.38% TTM	+134.59%
Zydus Lifesciences Limited	1,18,703	1,190.00	25.85	19.20%	+21.11% TTM	-2.51% TTM	+22.32%
Dr. Reddy's Laboratories Ltd.	1,14,513	1,372.00	41.50	13.90%	-3.53% TTM	-51.90% TTM	+14.26%
Cipla Ltd.	1,13,110	1,400.10	39.63	14.90%	-0.74% TTM	-47.48% TTM	-6.88%
Mankind Pharma Limited	1,04,631	2,533.15	46.22	13.70%	+13.27% TTM	+27.60% TTM	+6.91%
Aurobindo Pharma Ltd.	97,878	1,701.10	26.38	13.60%	+9.09% TTM	+9.48% TTM	+47.79%
Lupin Ltd	92,145	2,015.00	17.65	28.40%	+24.22% TTM	+20.10% TTM	+0.84%
Glenmark Pharmaceuticals ltd	70,608	2,501.85	39.27	16.20%	+32.94% TTM	+138.48% TTM	+35.48%
Alkem Laboratories Limited	62,054	5,190.00	28.15	18.80%	+13.36% TTM	-5.52% TTM	-8.38%
Abbott India Ltd. S	57,685	27,146.85	35.73	41.90%	+6.29% TTM	+11.18% TTM	-7.56%
Biocon Ltd.	56,061	344.00	134.63	2.90%	+5.70% TTM	-55.37% TTM	-9.53%
Gland Pharma Limited	52,105	3,157.70	46.16	13.70%	+17.57% TTM	+46.55% TTM	+65.09%
Ipca Laboratories Ltd.	50,051	1,973.15	36.40	16.40%	+10.59% TTM	+67.91% TTM	+52.33%
GlaxoSmithkline Pharmaceuticals Ltd.	42,904	2,532.60	37.42	55.40%	+12.12% TTM	+20.03% TTM	-4.84%
Ajanta Pharma Ltd.	41,406	3,313.55	32.79	29.40%	+25.01% TTM	+29.70% TTM	+26.89%
Emcure Pharmaceuticals Limited	41,254	2,174.55	37.75	25.10%	+21.12% TTM	+33.34% TTM	+64.07%
J.B. Chemicals & Pharmaceuticals Lt	38,731	2,412.25	47.77	21.90%	+5.87% TTM	+7.56% TTM	+45.79%
Sai Life Sciences Limited	32,855	1,546.30	90.80	18.10%	—	—	+67.49%
PIRAMAL PHARMA LIMITED	31,659	237.80	-151.21	0.80%	+9.43% TTM	-781.93% TTM	+18.60%
ACUTAAS CHEMICALS LIMITED	30,928	3,777.65	70.51	27.70%	+45.18% TTM	+95.78% TTM	+106.30%
Wockhardt Ltd	30,869	1,899.80	76.22	6.40%	+25.70% TTM	+894.12% TTM	+39.18%
RUBICON RESEARCH LIMITED	28,416	1,716.55	98.59	24.30%	—	—	+164.06%
Fredun Pharmaceuticals Limited S	2,497	1,509.60	57.40	25.10%	+50.27% TTM	+89.63% TTM	+192.87%

Filings & corporate actions

Recent announcements

Fredun Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 05/11/2026 ,inter alia, to consider and approve Unaudited Standalone ....31 Oct 2026 · Board Meeting / Board Meeting
Allotment of 44000 Equity shares to Non- Promoters Allottees pursuant to conversion of Warrents.23 Oct 2026 · Company Update / Allotment of Equity Shares
Allotment of 44,000 Equity Shares to Non-Promoter Allottees pursuant to conversion of 14,667 Warrants into Equity Shares, consequent to the 1:2 Bonus Issue.23 Oct 2026 · Others / Outcome without intimation
Certificate pursuant to Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018.12 Oct 2026 · Company Update / Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
Press Release Issued by Fredun Pharmaceuticals Limited dated 08 October, 2026.8 Oct 2026 · Company Update / Press Release / Media Release
Revised Allotment of Rs. 182400 Equity Shares.5 Oct 2026 · Company Update / Allotment of Equity Shares
Revised Outcome of Board Meeting Dated 03rd October, 2026.5 Oct 2026 · Company Update / General
ALLOTMENT OF EQUITY SHARES PURSUANT TO CONVERSION OF WARRANTS.3 Oct 2026 · Company Update / Allotment of Equity Shares
Allotment of 1,82,400 Equity Shares to Non-Promoter Allottees pursuant to conversion of 60,800 Warrants into Equity Shares, consequent to the 1:2 Bonus Issue.3 Oct 2026 · Others / Outcome without intimation
Intimation of Trading Window Closure28 Sep 2026 · Insider Trading / SAST / Closure of Trading Window
Revised Allotment of Equity Shares pursuant to conversion of warrants.22 Sep 2026 · Company Update / Allotment of Equity Shares
Revised Outcome of Board Meeting Dated 16th September, 202622 Sep 2026 · Company Update / General
Press Release by FPL dated- 22-09-202622 Sep 2026 · Company Update / Press Release / Media Release
Allotment of 271200 Equity Shares upon Conversion of Warrants.16 Sep 2026 · Company Update / Allotment of Equity Shares
Allotment of 2,71,200 Equity Shares to Non-Promoter upon conversion of Warrants into Equity Shares.16 Sep 2026 · Others / Outcome without intimation
Press Release15 Sep 2026 · Company Update / Press Release / Media Release (Revised)
PRESS RELEASE15 Sep 2026 · Company Update / Press Release / Media Release
Press Release issued by Fredun Pharmaceuticals Limited8 Sep 2026 · Company Update / Press Release / Media Release
Press Release issued by Fredun Pharmaceuticals Limited dated 04.09.20264 Sep 2026 · Company Update / Press Release / Media Release
Intimation regarding permission to trade and admission of Equity Shares to dealing on the National Stock Exchange of India17 Aug 2026 · Company Update / General
Transcript of the Earnings Conference call held on 13th August, 2026 for Q1 FY27.17 Aug 2026 · Company Update / Earnings Call Transcript
Statement of Deviation or Variation For the Quarter Ended June 30, 2026.14 Aug 2026 · Company Update / Reg. 32 (1), (3) - Statement of Deviation & Variation
Monitoring Agency Report dated 14.08.202614 Aug 2026 · Company Update / Monitoring Agency Report
Audio Recording Q1 FY27 'Earnings Conference Call' of Fredun Pharmaceuticals Limited.13 Aug 2026 · Company Update / Analyst / Investor Meet
Intimation of Earnings Conference Call for the quarter Q1 of FY27.8 Aug 2026 · Company Update / Analyst / Investor Meet
Newspaper Advertisement of the Un-Audited Financial Results for Quarter ended 30th June, 20266 Aug 2026 · Company Update / Newspaper Publication
Newspaper Advertisement of the Un-Audited Financial Results for Quarter ended 30th June, 20266 Aug 2026 · Company Update / Press Release / Media Release
Press Release issued by Fredun Pharmaceuticals Limited6 Aug 2026 · Company Update / Press Release / Media Release
Outcome of the Board Meeting5 Aug 2026 · Result / Financial Results
In compliance to Regulation 30 and 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the Un-Audited Financial Results of the Company for the quarter ended ....5 Aug 2026 · Board Meeting / Outcome of Board Meeting
Fredun Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 05/08/2026 ,inter alia, to consider and approve Notice is hereby given ....30 Jul 2026 · Board Meeting / Board Meeting
Allotment of Bonus Equity Shares.17 Jul 2026 · Company Update / Allotment of Equity Shares
Intimation of Record Date pursuant to SEBI LODR Regulations, 2015 for Issue of Bonus Equity Shares.10 Jul 2026 · Corp. Action / Record Date
Certificate pursuant to Regulation 74(5) of the SEBI (Depositories and Participants) Regulation, 20188 Jul 2026 · Company Update / Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
Scrutinizer''s Report for 39th Annual General Meeting.30 Jun 2026 · AGM/EGM / AGM
Outcome of 39th Annual General Meeting30 Jun 2026 · AGM/EGM / AGM
Intimation of Closure of Trading Window24 Jun 2026 · Insider Trading / SAST / Closure of Trading Window
Transcript of the Earnings conference call held on 10th June 2026 for Q4 FY26.12 Jun 2026 · Company Update / Earnings Call Transcript
Audio Recording of the Q4 and year ended for the FY26 'Earnings Conference Call'10 Jun 2026 · Company Update / Analyst / Investor Meet
Newspaper Clipping- Information regarding 39th Annual General Meeting to be held on 30th June, 2026 through video conference/other audio visual means.9 Jun 2026 · Company Update / Newspaper Publication

Corporate actions

Purpose	Ex date	Record date	Payment date
Bonus issue 2:1	16 Jul 2026	16 Jul 2026	—
Final Dividend - Rs. - 0.7000	23 Jun 2026	23 Jun 2026	—
Final Dividend - Rs. - 0.7000	23 Sep 2025	23 Sep 2025	—
Final Dividend - Rs. - 0.7000	23 Sep 2024	23 Sep 2024	—

Board meetings

5 Nov 2026 Board Meeting - Financial Results
5 Aug 2026 Board Meeting - Financial Results